Table 2.
Laboratory data and novel renal biomarkers prior to creatine supplementation or placebo (baseline—pre)
| Parameter | Placebo (N = 10) | G3 (N = 10) | G5 (N = 10) | P* |
|---|---|---|---|---|
| Serum albumin (g/dl) | 3.9 ± 1.1 | 3.8 ± 1.3 | 4 ± 0.8 | 0.103 |
| Serum creatinine (mg/dl) | 0.9 ± 0.2 | 0.7 ± 0.12 | 0.9 ± 0.21 | 0.170 |
| Serum urea (mg/dl) | 21.3 ± 7.9 | 24.6 ± 4.2 | 27.1 ± 8.4 | 0.938 |
| eGFR (ml/min 1.73 m2) | 128 ± 25 | 121 ± 16 | 124 ± 19 | 0.787 |
| Proteinuria (mg/dl) | 3.2 ± 1.4 | 2.9 ± 1.9 | 3.8 ± 1.8 | 0.101 |
| Proteinuria (mg/g-Cr) | 54.9 ± 42.8 | 75.9 ± 78.1 | 36.9 ± 23.1 | 0.901 |
| Albuminuria (mg/L) | 6.9 ± 0.65 | 6.6 ± 0.5 | 6.1 ± 0.5 | 0.319 |
| uKIM-1 (pg/ml) | 43 (22–157) | 63 (26–140) | 68 (20–169) | 0.432 |
| uKIM-1 (pg/mg-Cr) | 85 (69–117) | 117 (81–298) | 87 (25–177) | 0.827 |
| MCP-1 (pg/ml) | 55 (31–108) | 35 (23–43) | 42 (29–100) | 0.575 |
| MCP-1 (pg/mg-Cr) | 69 (28–112) | 94 (40–147) | 52 (29–122) | 0.794 |
Data are presented as mean ± standard deviation or as median and interquartile range in parenthesis. eGFR, estimated glomerular filtration rate using the CKD-EPI formula; uKIM-1, urinary kidney injury molecule-1; uMCP-1, urinary monocyte chemotactic protein-1. ANOVA for normal data and Kruskal–Wallis test for non-normal data.
*Significant P < 0.05. (P > 0.05 shows that all groups are homogeneous).